ANI PHARMACEUTICALS INCANIP财报
Nasdaq · 医疗保健 · 药物制剂
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
营收
$211.4M
毛利润
N/A
营业利润
$13.9M
净利润
$8.5M
毛利率
N/A
营业利润率
6.6%
净利率
4.0%
同比增长
53.1%
EPS
$0.36
ANI PHARMACEUTICALS INC 2025财年Q2 财务摘要
ANI PHARMACEUTICALS INC 2025财年Q2营收 $211.4M（同比增长 53.1%），净利润 $8.5M（同比增长 473.8%）（净利率 4.0%）。
核心财务指标
| 总营收 | $211.4M |
|---|---|
| 净利润 | $8.5M |
| 毛利率 | N/A |
| 营业利润率 | 6.6% |
| 报告期 | 2025财年Q2 |
营收拆解
ANI PHARMACEUTICALS INC 2025财年Q2营收 $211.4M 共来自 6 个业务板块，最大板块 Sales Of Generic Pharmaceutical Products 贡献 $90.3M（占 42.7%）。
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Sales Of Generic Pharmaceutical Products | $90.3M | 42.7% |
| Sales Of Cortrophin Gel | $81.6M | 38.6% |
| Sales Of ILUVIEN And YUTIQ | $22.3M | 10.6% |
| Sales Of Established Brands | $13.2M | 6.2% |
| Unapproved Products | $6.1M | 2.9% |
| Sales Of Royalties And Other Pharmaceutical Services | $3.9M | 1.9% |
ANI PHARMACEUTICALS INC 分部营收 — 季度趋势
ANI PHARMACEUTICALS INC 过去 4 个季度各业务板块营收走势，展示 Sales Of Generic Pharmaceutical Products和Sales Of Cortrophin Gel 等业务的变化。
| 业务分部 | 2025财年Q4 | 2025财年Q3 | 2025财年Q2 | 2025财年Q1 |
|---|---|---|---|---|
| Sales Of Generic Pharmaceutical Products | $100.8M | $94.4M | $90.3M | $98.7M |
| Sales Of Cortrophin Gel | $111.4M | $101.8M | $81.6M | $52.9M |
| Sales Of ILUVIEN And YUTIQ | $19.8M | $16.6M | $22.3M | $16.1M |
| Sales Of Established Brands | $12.3M | $10.7M | $13.2M | $25.1M |
| Unapproved Products | $6.5M | $6.0M | $6.1M | $5.5M |
ANI PHARMACEUTICALS INC 年度营收
ANI PHARMACEUTICALS INC 历年营收汇总，含各年度总量（例如 2025 年营收为 $883.4M）
| 年份 | 年营收 |
|---|---|
| 2025 | $883.4M |
| 2024 | $614.4M |
| 2023 | $486.8M |
| 2022 | $316.4M |
ANI PHARMACEUTICALS INC 季度营收与净利润历史
ANI PHARMACEUTICALS INC 最近 8 个季度的营收、净利润及同比增速
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| 2025财年Q4 | $247.1M | +29.6% | $27.5M | 11.1% |
| 2025财年Q3 | $227.8M | +53.6% | $26.6M | 11.7% |
| 2025财年Q2 | $211.4M | +53.1% | $8.5M | 4.0% |
| 2025财年Q1 | $197.1M | +43.4% | $15.7M | 8.0% |
| 2024财年Q4 | $190.6M | +44.8% | $-10.3M | -5.4% |
| 2024财年Q3 | $148.3M | +12.5% | $-24.2M | -16.3% |
| 2024财年Q2 | $138.0M | +18.4% | $-2.3M | -1.7% |
| 2024财年Q1 | $137.4M | +28.7% | $18.2M | 13.2% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $137.4M | $138.0M | $148.3M | $190.6M | $197.1M | $211.4M | $227.8M | $247.1M |
| 同比增长 | 28.7% | 18.4% | 12.5% | 44.8% | 43.4% | 53.1% | 53.6% | 29.6% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $914.5M | $920.8M | $1.29B | $1.28B | $1.29B | $1.34B | $1.41B | $1.44B |
| 总负债 | $437.7M | $440.1M | $856.6M | $855.9M | $849.0M | $881.4M | $902.3M | $899.7M |
| 股东权益 | $452.0M | $455.8M | $405.9M | $403.7M | $418.6M | $436.8M | $505.8M | $540.7M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $18.3M | $17.4M | $12.5M | $15.9M | $35.0M | $75.8M | $44.1M | $30.4M |